

RECEIVED

OCT 1 7 2000

TECH CENTER 1600/2900

Substitute Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
08213-007001Application No.  
09/423,546Information Disclosure Statement  
by Applicant

(Use several sheets if necessary)

(37 CFR 1.98(b))

Applicant  
Elliott Bennett-Guerrero et al.Filing Date  
November 12, 1999

Group Art Unit

1645

## U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
MS	AA	4,053,585	10/11/77	Allison et al.			
MS	AB	4,199,565	04/22/80	Fullerton			
MS	AC	4,235,871	11/25/80	Papahadjopoulos			
MS	AD	4,235,877	11/25/80	Fullerton			
MS	AE	4,241,046	12/23/80	Papahadjopoulos			
MS	AF	4,285,936	08/25/81	Pier et al.			
MS	AG	4,693,891	09/15/87	Collins et al.			
MS	AH	4,755,381	07/05/88	Cryz			
MS	AI	4,755,382	07/05/88	Flaherty			
MS	AJ	4,771,127	09/13/88	Cryz et al.			
MS	AK	4,777,136	10/11/88	Young			
MS	AL	4,844,894	07/04/89	Ribi			
MS	AM	4,946,677	08/07/90	Dorner et al.			
MS	AN	5,026,557	06/25/91	Estis et al.			
MS	AO	5,057,598	10/15/91	Pollack et al.			
MS	AP	5,059,591	10/22/91	Janoff et al.			
MS	AQ	5,114,712	05/19/92	Fukuda et al.			
MS	AR	5,179,018	01/12/93	Bogard, Jr. et al.			
MS	AS	5,370,872	12/06/94	Cryz et al.			
MS	AT	5,417,986	05/23/95	Reid et al.			
MS	AU	5,426,046	06/20/95	Kaplan et al.			

## Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
MS	AV	WO90/03186	04/05/90	PT WIPO				
MS	AX	WO91/15239	10/17/91	PT WIPO				
MS	AY	WO92/20370	11/26/92	PT WIPO				

Examiner Signature

RPSwartz

Date Considered

2-20-02

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08213-007001	Application No. 09/423,546
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Elliott Bennett-Guerrero et al.	
		Filing Date November 12, 1999	Group Art Unit 1645

RECEIVED

OCT 17 2000

TECH CENTER 1000/2557

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
01/10/99	BA	WO93/08834	05/13/93	PCT				

OCT 13 2000

 PATENT & TRADEMARK OFFICE  
 OCT 13 2000

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
mg	BB	Adhikari et al., "Septicaemic low birthweight neonates treated with human antibodies to endotoxin", Archives of Disease in Childhood, (1985) 382-384
mg	BC	Allan, Elizabeth et al., "Antibacteroides lipopolysaccharide IgG levels in healthy adults and sepsis patients", FEMS Immunology and Medical Microbiology 11 (1995) 5-12
mg	BD	Alving, Carl R., "Lipid A and Liposomes Containing Lipid A As Adjuvants for Vaccines", Vol. II: Immunopharmacology and Pathophysiology, Ch. 18, 429-438
mg	BE	Alving, Carl R., "Macrophages as targets for delivery of liposome-encapsulated antimicrobial agents", Advanced Drug Delivery Reviews, 2 (1988) 107-128
mg	BF	Alving, Carl R., "Delivery of Liposome-Encapsulated Drugs to Macrophages", Pharmac. Ther. Vol. 22 (1983) pp. 407-424
mg	BG	Alving, Carl R., "Lipopolysaccharide, Lipid A, and Liposomes Containing Lipid A as Immunologic Adjuvants", Immunogiol. Vol. 187 (1993) 430-446
mg	BH	Alving, Carl R. et al., "Adjuvanticity of Lipid A and Lipid A Fractions in Liposomes", Elsevier North Holland, Inc. (1980) 67-78
mg	BI	Alving, Carl R., "Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens", Biochimica et Biophysica Acta, 1113 (1992) 307-322
mg	BJ	Alving, Carl R., "Liposomes as carriers of antigens and adjuvants", Journal of Immunological Methods, 140 (1991) 1-13
mg	BK	Alving, Carl R., "Liposomes as Carriers for Vaccines", Walter Reed Army Institute of Research, Washington, DC, Ch. 6 195-218
mg	BL	Alving, Carl R., "Liposomes containing lipid A: a potent nontoxic adjuvant for a human malaria sporozoite vaccine", Immunology Letters, 25 (1990) 275-280
mg	BM	Appelmek, B.J. et al., "Recombinant Human Bactericidal/Permeability-Increasing Protein (rBPI23) Is a Universal Lipopolysaccharide-Binding Ligand", Injection and Immunity (1994) 3564-3567
mg	BN	Appelmek, B.J. et al., "Antigenic and immunogenic differences in lipopolysaccharides of escherichia coli J5 vaccine strains of different origins", Jour of General Microbiology (1993) 3641-2647
mg	BO	Ashton, F.E. et al., "Short communication - Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide", Microbial Pathogenesis (1989) 455-458
mg	BP	Astiz, Mark E. et al., "Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: A prospective double-blind, randomized, controlled trial", Critical Care Medicine, Vol. 23, No. 1 (1995) 9-17
mg	BQ	Baker, Phillip J. et al., "Structural Features that Influence the Ability of Lipid A and Its Analogs to Abolish Expression of Suppressor T Cell Activity", Infection and Immunity, July 1992, 2694-2701
mg	BR	Baker, Phillip J. et al., "Ability of Monophosphoryl Lipid A to Augment the Antibody Response of Young Mice", Infection and Immunity, Dec. 1988, 3064-3066

Examiner Signature

RPSwartz


Date Considered


2-20-02

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08213-007001	Application No. 09/423,546
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Elliott Bennett-Guerrero et al.	
		Filing Date November 12, 1999	Group Art Unit 1645

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	CA	Bakouche, Ouahid et al., "Interleukin 1 Release by Human Monocytes Treated with Liposome-Encapsulated Lipopolysaccharide", Journal of Immunology, Vol. 139 (1987) 1120-1126
me	CB	Barclay, G.R. et al., "Serological Relationships between Escherichia coli and Salmonella Smooth- and Rough-Mutant Lipopolysaccharides as Revealed by Enzyme-Linked Immunosorbent Assay for Human Immunoglobulin G Antiendotoxin Antibodies", Infection and Immunity (1987) 2706-2714
me	CC	Battafarano, Richard J. et al., "Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro", Surgery (1995) 318-324
me	CD	Baumgartner, Jean-Daniel, "Immunotherapy with Antibodies to Core Lipopolysaccharide: A Critical Appraisal", Infection Disease of North America, Vol. 5, No. 4 (1991) 915-927
me	CE	Baumgartner, Jean Daniel et al., "Prevention of Gram-Negative Shock and Death in Surgical Patients by Antibody to Endotoxin Core Glycolipid", The Lancet Ltd. (1985) 59-63
me	CF	Baumgartner, J.D. et al., "Interpretation of Data Regarding the Protection Afforded by Serum, IgG, or IgM Antibodies after Immunization with the Rough Mutant R595", Journal of Infectious Diseases, Vol. 160, No. 2 (1989) 347-349
me	CG	Baumgartner, Jean-Daniel et al., "Immunotherapy of Endotoxemia and Septicemia", Immunobiol., Vol. 187 (1993) 464-477
me	CH	Beeson, Paul B. M.D., "Tolerance to Bacterial Pyrogens", Medical Service, Grady Hospital and the Dept. of Medicine (1947) 39-44
me	CI	Bennett-Guerrero, Elliott et al., "Relationship of Preoperative Antiendotoxin Core Antibodies and Adverse Outcomes Following Cardiac Surgery", JAMA, Vol. 277, No. 8 (1997) 646-650
me	CJ	Bhattacharjee, Apurba K. et al., "Affinity-Purified Escherichia coli J5 Lipopolysaccharide-Specific IgG Protects Neutropenic Rats Against Gram-Negative Bacterial Sepsis", Journal of Infectious Diseases (1994) 170:622-629
me	CK	Bion, Julian F. et al., "Selective decontamination of the digestive tract reduces Gram-negative pulmonary colonization but not systemic endotoxemia in patients undergoing elective liver transplantation", Critical Care Medicine, Vol. 22, No. 1 (1994) 40-49
me	CL	Bone, Roger C. et al., "Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis", ACCP/SCCM Consensus Conference (1992) 1644-1655
me	CM	Boom, S.J. et al., "Abolition of the Hyperdynamic Cardiovascular State Induced by Endotoxaemia with a Murine IgG Monoclonal Antibody to Endotoxin", 12 pages
me	CN	Boom, S.J. et al., "Comparison of HA-1A and E5 Monoclonal Antibodies to Endotoxin in Rats with Endotoxaemia", Eur J. Surg, 159, (1993) 559-561
me	CO	Bosenberg, A.T. et al., "Strenuous exercise causes systemic endotoxemia", Am. Physiological Society (1988) 106-108
me	CP	Brandenburg, Klaus et al., "A comment on the preparation of liposomes from and on the $\beta \leftrightarrow \alpha$ acyl chain melting behavior of rough mutant lipopolysaccharide", Biochimica et Biophysica Acta (1991) 1-4
me	CQ	Braude, Abraham et al., "Passive Immunization Against the Local Shwartzman Reaction", Journal of Immunology, Vol. 108, No. 2 (1972) 505-512
me	CR	Brock-Utne, J.G. et al., "Endotoxaemia in exhausted runners after a long race", SAMJ, Vol. 73, (1988) 533-536

Examiner Signature 	Date Considered 2-20-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08213-007001	Application No. 09/423,546
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Elliott Bennett-Guerrero et al.	
		Filing Date November 12, 1999	Group Art Unit 1645

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
mg	DA	Bresee, Joseph S. et al., "Hepatitis C Virus Infection Associated with Administration of Intravenous Immune Globulin", JAMA, Vol. 276, No. 19 (1996) 1563-1567
mg	DB	Brown, Anna et al., "The antibody response to salmonellae in mice and humans studied by immunoblots and ELISA", Microbial Pathogenesis (1989) 6:445-454
mg	DC	Bruderer, Urs et al., "Qualitative analysis of antibody binding", Journal of Immunological Methods, (1990) 133:263-268
mg	DD	Bruins, Scott C. et al., "Immunization with R Mutants of <i>Salmonella Minnesota</i> ", Infection and Immunity (1977) 16-20
mg	DE	Bruins, Scott C. et al., "Parameters Affecting the Enzyme-Linked Immunosorbent Assay of Immunoglobulin G Antibody to a Rough Mutant <i>Salmonella Minnesota</i> ", Infection and Immunity (1978) 721-728
mg	DF	Butler, Patrice et al., "M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria", Journal of Hepatology (1993) 17:408-414
mg	DG	Cafiero, Ferdinando et al., "Prophylaxis of infection with intravenous immunoglobulins plus antibiotic for patients at risk for sepsis undergoing surgery for colorectal cancer: Results of a randomized, multicenter clinical trial", Surgery, Vol. 112, No. 1 (1991) 24-31
mg	DH	Carrico, C. James et al., "Multiple-Organ-Failure Syndrome", Arch Surg, Vol. 121 (1986) 196-208
mg	DI	Cho, Norio et al., "Delayed Hypersensitivity in Murine Salmonellosis: Specificity of Footpad Reaction in Mice Infected with Rough Mutants of <i>Salmonella typhimurium</i> ", Microbiol. Immunol., Vol. 27 (2) (1983) 167-175
mg	DJ	Christ, William J. et al., "E5531, a Pure Endotoxin Antagonist of High Potency", Science, Vol. 268 (1995) 80-83
mg	DK	Cohen, J. et al., "Antibody Titres to a Rough-Mutant Strain of <i>Escherichia Coli</i> in Patients Undergoing Allogeneic Bone-Marrow Transplantation", The Lancet (1987) 8-10
mg	DL	Cometta, Alain et al., "Prophylactic Intravenous Administration of Standard Immune Globulin as Compared with Core-Lipopolysaccharide Immune Globulin in Patients at High Risk of Postsurgical Infection", N.E. Journal of Medicine, Vol. 327, No. 4 (1992) 234-240
mg	DM	Cremer, Natalie et al., "Influence of Stress on Distribution of Endotoxin in RES Determined by Fluorescein Antibody Technic", Stress on Distribution of Endotoxin in RES (1957) 310-513
mg	DN	Cross, Alan et al., "Safety and Immunogenicity of a Polyvalent <i>Escherichia coli</i> Vaccine in Human Volunteers", Journal of Infectious Diseases (1994) 170:834-40
mg	DO	Cross, Alan et al., "The Human Antibody Response During Natural Bacteremic Infection with Gram-Negative Bacilli against Lipopolysaccharide Core Determinants", Journal of Infectious Diseases, Vol. 160, No. 2 (1989) 225-236
mg	DP	Crowley, James et al., "Opsonization of serum-sensitive and serum-resistant <i>Escherichia coli</i> by rough mutant (Re) antisera", J. Lab. Clin. Med., Vol. 99, No. 2 (1982) 197-205
mg	DQ	Cryz, S.J. Jr. et al., "Immunization with a <i>Pseudomonas aeruginosa</i> Immunotype 5 O Polysaccharide-Toxin A Conjugate Vaccine: Effect of a Booster Dose on Antibody Levels in Humans", Infection and Immunity, Vol. 56, No. 7 (1988) 1829-1830

Examiner Signature RPSwartz	Date Considered 2-20-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08213-007001	Application No. 09/423,546
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Elliott Bennett-Guerrero et al.	
		Filing Date November 12, 1999	Group Art Unit 1645

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
<i>RLS</i>	EA	Cryz, S.J. et al., "Safety and Immunogenicity of <i>Escherichia coli</i> O18 O-Specific Polysaccharide (O-PS)-Toxin A and O-PS-Cholera Toxin Conjugate Vaccines in Humans", Journal of Infectious Diseases (1991) 163:1040-1045
<i>RLS</i>	EB	Cullis, Pieter R. et al., "Liposomes as Pharmaceuticals", 39-72
<i>RLS</i>	EC	Daemen, Toos et al., "Differential Effects of Liposome-Incorporation on Liver Macrophage Activating Potencies of Rough Lipopolysaccharide, Lipid A and Muramyl Dipeptide", Journal of Immunology, Vol. 142, No. 7 (1989) 2469-2474
<i>RLS</i>	ED	Dale, Peter A. et al., "Human Vaccination with <i>Escherichia coli</i> J5 Mutant Induces Cross-Reactive Bactericidal Antibody Against <i>Neisseria gonorrhoeae</i> Lipooligosaccharide", Journal of Infectious Diseases (1992) 166:316-325
<i>RLS</i>	EF	Dancey, George F. et al., "Enhancement of Liposomal Model Membrane Immunogenicity by Incorporation of Lipid A1", Journal of Immunology, Vol. 119, No. 6 (1977) 1868-1873
<i>RLS</i>	EG	Danner, Robert L. et al., "Endotoxemia in Human Septic Shock", Chest (1991) 169-175
<i>RLS</i>	EH	Deitch, Edwin A. et al., "Endotoxin-induced bacterial translocation and mucosal permeability: Role of xanthine oxidase, complement activation, and macrophage products", Critical Care Medicine, Vol. 19, No. 6 (1991) 785-791
<i>RLS</i>	EI	Deitch, Edwin A., "The Role of Intestinal Barrier Failure and Bacterial Translocation in the Development of Systemic Infection and Multiple Organ Failure", Arch Surg, Vol. 125 (1990) 403-404
<i>RLS</i>	EJ	Deitch, Edwin A., "Bacterial Translocation of the Gut Flora", Journal of Trauma, Vol. 30, No. 12, (1990) S184-S189
<i>RLS</i>	EK	DeKievit, Teresa R. et al., "Monoclonal Antibodies That Distinguish Inner Core, Outer Core, and Lipid A Regions of <i>Pseudomonas aeruginosa</i> Lipopolysaccharide", Journal of Bacteriology, Vol. 176, No. 23 (1994) 7129-7139
<i>RLS</i>	EL	Delahooke, D.M. et al., "Tumor Necrosis Factor Induction by an Aqueous Phenol-Extracted Lipopolysaccharide Complex from <i>Bacteroides</i> Species", Infection and Immunity (1995) 840-846
<i>RLS</i>	EM	Desiderio, James V. et al., "Immunization Against Experimental Murine Salmonellosis with Liposome-Associated O-Antigen", Infection and Immunity, Vol. 48, No. 3 (1985) 658-663
<i>RLS</i>	EN	Dijkstra, Jan et al., "A procedure for the efficient incorporation of wild-type lipopolysaccharide into liposomes for use in immunological studies", Journal of Immunological Methods, 114 (1988) 197-205
<i>RLS</i>	EO	Dijkstra, Jan et al., "Altered In Vivo Activity of Liposome-Incorporated Lipopolysaccharide and Lipid A", Infection and Immunity (1989) 3357-3363
<i>RLS</i>	EP	Dijkstra, Jan et al., "Modulation of the Biological Activity of Bacterial Endotoxin by Incorporation into Liposomes", Journal of Immunology, Vol. 138, No. 8 (1987) 2663-2670
<i>RLS</i>	EQ	Din, Zafeer Z et al., "Effect of pH on Solubility and Ionic State of Lipopolysaccharide Obtained from the Deep Rough Mutant of <i>Escherichia coli</i> ", Biochemistry 32 (1993) 4579-4586
<i>RLS</i>	ER	Ding, H.F. et al., "Protective immunity induced in mice by detoxified salmonella lipopolysaccharide", J. Med. Microbiol., Vol. 31 (1990) 95-102
<i>RLS</i>	ES	DiPadova, Franco E. et al., "Anti-Lipopolysaccharide Core Antibodies", Bacterial Endotoxins: Basic Science (1994) 85-94

Examiner Signature <i>R.P. Swant</i>	Date Considered 2-20-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08213-007001	Application No. 09/423,546
<b>Information Disclosure Statement</b> <b>by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Elliott Bennett-Guerrero et al.	
		Filing Date November 12, 1999	Group Art Unit 1645

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
RA	FA	Dominioni, Lorenzo et al., "Effects of High-Dose IgG on Survival of Surgical Patients with Sepsis Scores of 20 or Greater", Arch Surg, Vol. 126 (1991) 236-240
RA	FB	Donnelly, John J. et al., "Immunogenicity of a Haemophilus influenzae Polysaccharide-Neisseria meningitidis Outer Membrane Protein Complex Conjugate Vaccine", Journal of Immunology, Vol. 145, No. 9 (1990) 3071-3079
RA	FC	Dunn, David L. et al., "Immunotherapy of gram-negative bacterial sepsis: Enhanced survival in a guinea pig model by use of rabbit antiserum to Escherichia coli J5", Surgery (1980) 212-219
RA	FD	Elkins, Karen L. et al., "Specific Immunological Unresponsiveness to Bacterial Lipopolysaccharides Develops in a Cyclic Manner", Infection and Immunity, Vol. 57, No. 7 (1989) 2253-2255
RA	FE	Evans, Martin E. et al., "Lipopolysaccharide Heterogeneity in Escherichia coli J5 Variants: Analysis by Flow Cytometry", Journal of Infectious Diseases (1992) 803-811
RA	FF	Evans, Martin E. et al., "Fluorescence-Activated Cell Sorter Analysis of Binding by Lipopolysaccharide-Specific Monoclonal Antibodies to Gram-Negative Bacteria", Journal of Infectious Diseases (1990) 148-155
RA	FG	Field, Sue et al., "Development of an anti-idiotypic monoclonal antibody mimicking the structure of lipopolysaccharide (LPS) inner-core determinants", Microbial Pathogenesis (1993) 15: 103-120
RA	FH	Field, Susan et al., "An Anti-Idiotypic Antibody Which Mimics the Inner-Core Region of Lipopolysaccharide Protects Mice against a Lethal Challenge with Endotoxin", Infection and Immunity, Vol. 62 (1994) 3994-3999
RA	FI	Fink, Mitchell P. et al., "Increased Intestinal Permeability in Endotoxic Pigs", Arch Surg, Vol. 126 (1991) 211-218
RA	FJ	Fink, Mitchell P., Effect of Critical Illness on Microbial Translocation and Gastrointestinal Mucosa Permeability", Seminars in Respiratory Infections, Vol. 9, No. 4 (1994) 256-260
RA	FK	Fisher, C.J. Jr. et al., "Immunotherapy of Sepsis Syndrome: A Comparison of the Available Treatments", Klin Wochenschr (1991) 162-167
RA	FL	Fisher, Charles J. Jr. et al., "Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein", N.E. Journal of Medicine, Vol. 334, No. 26 (1996) 1697-1702
RA	FM	Fong, Yuman et al., "Endotoxemia Elicits Increased Circulating $\beta$ x-IFN/IL-6 in Man", Journal of Immunology, Vol. 142, No. 7 (1989) 2321-2324
RA	FN	Ford, Edward G. et al., "Sepsis After Coronary Bypass Grafting: Evidence for Loss of the Gut Mucosal Barrier", Ann Thorac Surg (1991) 514-517
RA	FO	Freed, Gary L. et al., "Safety of Vaccinations, Miss America, the Media and Public Health", JAMA, Vol. 276, No. 23 (1996) 1869-1872
RA	FP	Freeman, R. et al., "Prevention of fever and Gram negative infection after open heart surgery by antiendotoxin", Thorax (1985) 40: 846-848
RA	FQ	Freudenberg, M.A. et al., "Analysis of LPS released from <i>Salmonella abortus equi</i> in human serum", Microbial Pathogenesis (1991) 10: 93-104
RA	FR	Fries, Louis F. et al., "Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy", Proc. Natl. Acad. Sci. USA, Vol. 89 (1992) 358-362
RA	FS	Gaffin, S.L. et al., "Hypoxia-Induced Endotoxemia in Primates: Role of Reticuloendothelial System Function and Anti-Lipopolysaccharide Plasma", Aviation, Space and Environmental Medicine (1986) 1044-1049

Examiner Signature R.P. Swartz	Date Considered 2-20-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08213-007001	Application No. 09/423,546
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Elliott Bennett-Guerrero et al.	
		Filing Date November 12, 1999	Group Art Unit 1645
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
<i>MS</i>	GA	Gaffin, S.L. et al., "The use of antilipoplysaccharide (anti-LPS) antibodies in the management of septic shock", SA Mediese Tydskrif Deel 65 (1984) 158-161
<i>MS</i>	GB	Gaffin, Stephen L. et al., "An ELISA procedure for detecting human anti-endotoxin antibodies in serum", Ann Clin Biochem (1983) 19: 191-194
<i>MS</i>	GC	Gaffin, Stephen L., "Large-Scale Production of Anti-Gram Negative Bacterial Antibodies", The Lancet (1983) 1420-1421
<i>MS</i>	GD	Gaffin, Stephen L., "Anti-lipoplysaccharide toxin therapy for whole body X-irradiation overdoses", The British Journal of Radiology (1985) 58: 881-884
<i>MS</i>	GE	Gaffin, S.L. et al., "A morphological study of the action of equine anti-lipoplysaccharide plasma on gram-negative bacteria", J. Med. Microbiol., Vol. 24 (1987) 165-168
<i>MS</i>	GF	Gaffin, Stephen L. et al., "Effect of corticosteroid prophylaxis on lipopolysaccharide levels associated with intestinal ischemia in cats", Critical Care Medicine, Vol. 14, No. 10 (1986) 889-891
<i>MS</i>	GG	Gaffin, Stephen L. et al., "Properties of Human Anti-Lipopolysaccharide Gamma Globulin: Specificity and Protective Effects", Vox Sang (1985) 48: 276-283
<i>MS</i>	GH	Galanos, Chris et al., "Mechanisms of Endotoxin Shock and Endotoxin Hypersensitivity", Immunobiol., Vol. 187 (1993) 346-356
<i>MS</i>	GI	Gathiram, P. et al., "Time Course of Endotoxemia and Cardiovascular Changes in Heat-Stressed Primates", Aviation, Space and Environmental Medicine (1987) 1071-1074
<i>MS</i>	GK	Gathiram, P. et al., "Superior Mesenteric Artery Occlusion Shock in Cats: Modification of the Endotoxemia by Antilipoplysaccharide Antibodies (Anti-LPS), Circulatory Shock (1986) 19: 231-237
<i>MS</i>	GL	Gathiram, P. et al., "Antilipoplysaccharide Improves Survival in Primates Subjected to Heat Stroke", Circulatory Shock (1987) 23: 157-164
<i>MS</i>	GM	Gazzano-Santoro, Helene, "Competition between rBPI <sub>23</sub> , a Recombinant Fragment of Bactericidal/Permeability-Increasing Protein, and Lipopolysaccharide (LPS)-Binding Protein for Binding to LPS and Gram-Negative Bacteria", Infection and Immunity (1994) 1185-1191
<i>MS</i>	GN	Gigliotti, Francis et al., "Failure of Monoclonal Antibodies to Core Glycolipid to Bind Intact Smooth Strains of <i>Escherichia coli</i> ", The Journal of Infectious Diseases, Vol. 151, No. 6 (1985) 1005-1011
<i>MS</i>	GO	Gmeiner, Jobst et al., "Molecular Composition of the Outer Membrane of <i>Escherichia coli</i> and the Importance of Protein-Lipopolysaccharide Interactions", Arch Microbiol., Vol. 127 (1980) 81-86
<i>MS</i>	GP	Goldie, Anne S. et al., "Natural Cytokine Antagonists and Endogenous Antiendotoxin Core Antibodies in Sepsis Syndrome", JAMA, Vol. 274, No. 3 (1995) 172-177
<i>MS</i>	GQ	Goto, Masakatsu et al., "Early Endotoxin Tolerance in Suckling Rats", Research in Communications and Chemical Pathology and Pharmacology, Vol. 76, NO. 2 (1992) 249-252
<i>MS</i>	GR	Goris, Jan A. et al., "Multiple-Organ Failure", Arch Surg, Vol. 120 (1985) 1109-1115
<i>MS</i>	GS	Gould, F.K. et al., "Antibody to endotoxin is associated with decreased frequency of postoperative infection", Am J Obstet Gynecol (1988) 317-319
<i>MS</i>	GR	Gregoriadis, Gregory, "Immunological adjuvants: a role for liposomes", Immunology Today, Vol. 11, No. 3 (1990) 89-97
<i>MS</i>	GS	Greenman, Richard L. et al., "A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis", JAMA, Vol. 266, No. 8 (1991) 1097-1102

Examiner Signature <i>RPSwartz</i>	Date Considered 2-20-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08213-007001	Application No. 09/423,546
<b>Information Disclosure Statement</b> <b>by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Elliott Bennett-Guerrero et al.	
		Filing Date November 12, 1999	Group Art Unit 1645 <i>[Signature]</i>

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
<i>[Signature]</i>	HA	Greisman, Sheldon E. M.D. et al., "Mechanisms of Endotoxin Tolerance, II. Relationship Between Endotoxin Tolerance and Reticuloendothelial System Phagocytic Activity in Man", Journal of Experimental Medicine, Vol. 119 (1963) 241-264
<i>[Signature]</i>	HB	Greisman, Sheldon E. et al., "Comparative Pyrogenic Reactivity of Rabbit and Man to Bacterial Endotoxin", PSEBM, Vol. 131 (1969) 1154-1158
<i>[Signature]</i>	HC	Greisman, Sheldon E. et al., "Mechanisms of Endotoxin Tolerance, I. Relationship Between Tolerance and Reticuloendothelial System Phagocytic Activity in the Rabbit", Journal of Experimental Medicine, (1962) 663-674
<i>[Signature]</i>	HD	Greisman, Sheldon E. et al., "Mechanisms of Endotoxin Tolerance with Special Reference to Man", Journal of Infectious Diseases, Vol. 128 (1973) S265-S276
<i>[Signature]</i>	HE	Greisman, Sheldon E. et al., "Mechanisms of Endotoxin Tolerance, V. Specificity of the Early and Late Phases of Pyrogenic Tolerance", The Journal of Immunology, Vol. 103, No. 6 (1969) 1223-1236
<i>[Signature]</i>	HF	Greisman, Sheldon E., "Induction of Endotoxin Tolerance", Beneficial Effects of Endotoxins (1983) 149-178
<i>[Signature]</i>	HG	Greisman, Sheldon E. et al., "Experimental Gram-Negative Bacterial Sepsis: Prevention of Mortality Not Preventable by Antibiotics Alone", Infection and Immunity, Vol. 25 (1979) 538-557
<i>[Signature]</i>	HH	Gruner, Sol. M. et al., "Materials Properties of Liposomal Bilayers" 1-38
<i>[Signature]</i>	HI	Haishima, Yuji et al., "Structural investigation on the lipopolysaccharide of <i>Escherichia coli</i> rough mutant F653 representing the R3 core type", Eur. J. Biochem., Vol. 203 (1992) 127-134
<i>[Signature]</i>	HJ	Hancock et al., "E. Preparation of Lipopolysaccharide and Enterobacterial Common Antigen", Bacterial Cell Surface Techniques 91-97
<i>[Signature]</i>	HK	Hansorough, John M.D. et al., "Effects of Recombinant Bactericidal/Permeability-Increasing Protein (rBPI <sub>23</sub> ) on Neutrophil Activity in Burned Rats", Journal of Trauma: Injury, Infection, and Critical Care, Vol. 40, No. 6 (1996) 886-893
<i>[Signature]</i>	HL	Hodgson, Christopher J. et al., "Prophylactic use of human endotoxin-core hyperimmune gammaglobulin to prevent endotoxaemia in colostrums-deprived gnotobiotic lambs challenged orally with <i>Escherichia coli</i> ", FEMS Immunology and Medical Microbiology 11 (1995) 171-180
<i>[Signature]</i>	HM	Hoffman, William D. et al., "Endotoxin in Septic Shock", Anesth Analg (1993) 77: 613-624
<i>[Signature]</i>	HN	Inzana, Thomas J. Ph.D. et al., "Immune response to cattle to <i>Haemophilus somnus</i> lipid A-protein conjugate vaccine and efficacy in a mouse abortion model", Am J Vet Res, Vol. 53, No. 2 (1992) 175-179
<i>[Signature]</i>	HO	Jackson et al., "Lactam Antibiotic-Induced Release of Free Endotoxin: In Vitro Comparison of Penicillin-Binding Protein (PBP) 2-Specific Imipenem and PBP 3-Specific ...", Merck Institute for Therapeutic Research (1992) 1033-1041
<i>[Signature]</i>	HP	Jarvis et al., "Infection with hepatitis G virus among recipients of plasma products", The Lancet (1996) 348: 1352-1355
<i>[Signature]</i>	HQ	Jones et al., "Controlled Trial of Pseudomonas Immunoglobulin and Vaccine in Burn Patients", The Lancet (1980) 1263-1265
<i>[Signature]</i>	HR	Jones et al., "Controlled Trials of Polyvalent Pseudomonas Vaccine in Burns", The Lancet (1979) 977-983
<i>[Signature]</i>	HS	Jones, R.J., "Early Protection by Vaccines in Burns", Br. J. exp. Path. (1971) 52: 100-109

Examiner Signature

*RP Swartz*

Date Considered

*2-20-02*

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08213-007001	Application No. 09/423,546
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Elliott Bennett-Guerrero et al.	
		Filing Date November 12, 1999	Group Art Unit 1645
(37 CFR §1.98(b))			

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
PRG	IA	Jones, R.J., "Specificity of early protective responses induced by pseudomonas vaccines", J. Hyg. Camb. (1972) 70: 343-351
PRG	IB	Kreger, Bernard A. et al., "Gram-Negative Bacteremia, III. Reassessment of Etiology, Epidemiology and Ecology in 612 Patients", Am. Journal of Medicine, Vol. 68 (1980) 332-343
PRG	IC	Konstantinov, G. et al., "Passive Protection Against Heterologous Gram-Negative Bacteria Mediated by Antiserum to Epimeraseless Re Mutant of Salmonella Minnesota", Ann. Immunol. (Inst. Pasteur) (1982) 133: 71-76
PRG	ID	Kress, H.G. et al., "Prediction and Prevention, by Immunological Means, of Septic Complications After Elective Cardiac Surgery", Second Vienna Shock Forum (1989) 1031-1035
PRG	IE	Kuppermann, Nathan et al., "Comparison of a Recombinant Endotoxin-Neutralizing Protein with a Human Monoclonal Antibody to Endotoxin for the Treatment of <i>Escherichia coli</i> Sepsis in Rats", The Journal of Infectious Diseases (1994) 170: 630-635
PRG	IF	Lachman, Eylon et al., "Anti-Lipopolysaccharide Immunotherapy in Management of Septic Shock of Obstetric and Gynaecological Origin", The Lancet (1984) 981-983
PRG	IG	Girardin, Eric et al., "Treatment of Severe Infectious Purpura in Children with Human Plasma from Donors Immunized with <i>Escherichia coli</i> J5: A Prospective Double-Blind Study", The Journal of Infectious Diseases (1992) 165: 695-701
PRG	IH	Luderitz, O. et al., "Immunochemistry of O and R Antigens of Salmonella and Related Enterobacteriaceae", Bacteriological Reviews, Vol. 30, No. 1 (1966) 192-255
PRG	IJ	Marks, Melvin et al., "Induction of Immunity against Lethal <i>Haemophilus influenzae</i> by <i>Escherichia coli</i> Core Lipopolysaccharide", J. Clin. Invest., Vol. 69 (1982) 742-749
PRG	IK	Martich, G. Daniel et al., "Response of Man to Endotoxin", Critical Care Medicine Department, 8 pp
PRG	IL	Mattsby-Baltzer, Inger et al., "Antibodies to Lipid A: Occurrence in Humans", Reviews of Infectious Diseases, Vol. 6, No. 4 (1984) 553-557
PRG	IM	Mattsby-Baltzer, I. Et al., "Susceptibility of Lipopolysaccharide-Responsive and -Hyporesponsive Ity <sup>3</sup> Mice to Infection with Rough Mutants of <i>Salmonella typhimurium</i> ", Infection and Immunity, Vol. 64, No. 4 (1996) 1321-1327
PRG	IN	McCabe, William R. et al., "Type-Specific and Cross-Reactive Antibodies in Gram-Negative Bacteremia", The N.E. Journal of Medicine, Vol. 287, No. 6 (1972) 261-267
PRG	IO	McCallus, Daniel et al., "Antibody Specific for <i>Escherichia coli</i> J5 Cross-React to Various Degrees with an <i>Escherichia coli</i> Clinical Isolate Grown for Different Lengths of Time", Infection and Immunity, Vol. 55, No. 5 (1987) 1042-1046
PRG	IP	Mehta, N.D. et al., "Comparison of the opsonic activity of polyclonal and monoclonal antibodies raised against <i>Salmonella Minnesota</i> strain R595", J. Med. Microbiol., Vol. 25 (1988) 85-93
PRG	IQ	Mehta, N.E. et al., "A comparison of specificity and biological activity of polyclonal and monoclonal antibodies raised against <i>Salmonella Minnesota</i> R595 lipopolysaccharide, J. Med. Microbiol., Vol. 31 (1990) 85-93
PRG	IR	Michael, J. Gabriel et al., "Immune Response to Parental and Rough Mutant Strains of <i>Salmonella Minnesota</i> ", Infection and Immunity, Vol. 33, No. 3 (1981) 784-787
PRG	IS	Michie, Hamish R. et al., "Detection of Circulating Tumor Necrosis Factor After Endotoxin Administration", N.E. Journal of Medicine (1988) 318: 1481-1486

Examiner Signature <i>R.P. Swartz</i>	Date Considered 2-20-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08213-007001	Application No. 09/423,546
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Elliott Bennett-Guerrero et al.	
		Filing Date November 12, 1999	Group Art Unit 1645

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
PS	JA	Miyata, Tadanori, "Endotoxaemia Pulmonary Complications, and Thrombocytopenia in Liver Transplantation", The Lancet (1989) 189-191
PS	JB	Moore, Frederick et al., "Gut Bacterial Translocation via the Portal Vein: A Clinical Perspective with Major Torso Trauma", Journal of Trauma, Vol. 31, No. 5 (1991) 629-638
PS	JC	Morris, Debra et al., "Endotoxemia in neonatal calves given antiserum to a mutant <i>Escherichia coli</i> (J5)", Am J Vet Res, Vol. 47, No. 12 (1986) 2554-2565
PS	JD	Morris, Debra et al., "Evaluation of the opsonic capacity of core lipopolysaccharide antiserum of equine origin against smooth <i>Escherichia coli</i> 0111:B4, using macrophage chemiluminescence", Am J Vet Res, Vol. 50, No. 8 (1989) 1272-1278
PS	JE	Nelson, Douglas et al., "Recombinant endotoxin neutralizing protein improves survival from <i>Escherichia coli</i> sepsis in rats", Critical Care Medicine, Vol. 23, No. 1 (1995) 92-98
PS	JF	Mulholland, John J. et al., "Quantitative Studies of Febrile Tolerance and Levels of Specific Antibody Evoked by Bacterial Endotoxin", Journal of Clinical Investigation, Vol. 44, No. 6 (1965) 920-928
PS	JG	Mutharia, Lucy M. et al., "Monoclonal Antibodies Specific for <i>Escherichia coli</i> J5 Lipopolysaccharide: Cross-Reaction with Other Gram-Negative Bacterial Species", Infection and Immunity, Vol. 45, No. 3 (1984) 631-636
PS	JH	Munster, Andrew M. et al., "Translocation: Incidental Phenomenon or True Pathology?", Annals of Surgery, Vol. 218, No. 3 (1993) 321-327
PS	JI	Nelson, D. et al., "Influence of subinhibitory levels of antibiotics on expression of <i>Escherichia coli</i> lipopolysaccharide and binding of anti-lipopolysaccharide monoclonal antibodies", J. Med Microbiol., Vol. 39 (1993) 100-106
PS	JJ	Nelson, J.W. et al., "Production and characterization of mouse monoclonal antibodies reactive with the lipopolysaccharide core of <i>Pseudomonas aeruginosa</i> ", J. Med. Microbiol., Vol. 36 (1992) 358-365
PS	JK	Nevola, Joseph J. et al., "Colonization of the Mouse Intestine by an Avirulent <i>Salmonella typhimurium</i> Strain and Its Lipopolysaccharide-Defective Mutants", Infection and Immunity, Vol. 50, No. 1 (1985) 152-159
PS	JL	Ng, Ah-Kau et al., "Relationship of Structure to Function in Bacterial Endotoxins: Serologically Cross-reactive Components and their Effect on Protection of Mice Against Some Gram-negative Infections", J. Gen. Microbiol. (1976) 94: 107-116
PS	JM	Nikaido, Hiroshi et al., "Outer Membrane of <i>Salmonella Typhimurium</i> : Electron Spin Resonance Studies", Biochimica et Biophysica Acta (1977) 465: 152-164
PS	JN	Nys, Monique et al., "Protective Effects of Polyclonal Sera and Monoclonal Antibodies Active to <i>Salmonella Minnesota</i> Re595 Lipopolysaccharide during Experimental Endotoxemia", Journal of Infectious Diseases (1990) 162: 1087-1095
PS	JO	Ohshio, Gakuji et al., "The Effect of Splenectomy on Antibody Response to Lipopolysaccharide ( <i>E. coli</i> ) Immunization", Journal of Trauma, Vol. 28, No. 3 (1988) 379-382
PS	JP	Overbeek, Berry P. et al., "Carumonam Enhances Reactivity of <i>Escherichia coli</i> with Mono- and Polyclonal Antisera to Rough Mutant <i>Escherichia coli</i> J5", Journal of Clinical Microbiology, Vol. 25, NO. 6 (1987) 1009-1013
PS	JQ	Papa, M. et al., "The Effect of Ischemia of the Dog's Colon on Transmural Migration of Bacteria and Endotoxin", Journal of Surgical Research (1983) 35: 264-269

Examiner Signature RPSWARTZ	Date Considered 2-20-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08213-007001	Application No. 09/423,546
<b>Information Disclosure Statement</b> <b>by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Elliott Bennett-Guerrero et al.	
		Filing Date November 12, 1999	Group Art Unit 1645




















**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
MS	KA	Parent, James B. et al., "Reactivity of Monoclonal Antibody E5® With Endotoxin. II Binding to Short- and Long-Chain Smooth Lipopolysaccharides", <i>Circulatory Shock</i> (1992) 38: 63-73
MS	KB	Peter, G. et al., "Limited Protective Effect of Rough Mutant Antisera in Murine <i>Escherichia coli</i> Bacteremia", <i>Infection</i> 10 (1982) 228-232
MS	KC	Petrov, Alexander B. et al., "Non-specific modulation of the immune response with liposomal meningococcal lipopolysaccharide: role of different cells and cytokines", 7 pp
MS	KD	Pilz, Gunter et al., "Early Sepsis Treatment with Immunoglobulins After Cardiac Surgery in Score-identified High-risk Patients", <i>Chest</i> (1994) 76-82
MS	KE	Pollack, Matthew et al., "Enhanced Survival in <i>Pseudomonas aeruginosa</i> Septicemia Associated with High Levels of Circulating Antibody to <i>Escherichia coli</i> Endotoxin Core", <i>The Journal of Investigation</i> , Vol. 72 (1983) 1874-1881
MS	KF	Pollack, Matthew et al., "Specificity and Cross-Reactivity of Monoclonal Antibodies Reactive with the Core and Lipid A Regions of Bacterial Lipopolysaccharide", <i>The Journal of Infectious Diseases</i> , Vol. 159, No. 2 (1989) 168-188
MS	KG	Poxton, Ian R. et al., "Biological Activity of <i>Bacteroides</i> Lipopolysaccharide-Reappraisal", <i>Clinical Infectious Diseases</i> (1995) 20: S149-S153
MS	KH	Quezado, Zenaide M.N. et al., "A Controlled Trial of HA-1A in a Canine Model of Gram-negative Septic Shock", <i>JAMA</i> , Vol. 269, No. 17 (1993) 2221-2227
MS	KI	Raetz, Christian, "Bacterial Lipopolysaccharides: a Remarkable Family of Bioactive Macroamphiphiles", Chapter 69, (1995) 1-69
MS	KJ	Sakulramung, Reutai et al., "Cross-Reactive Immunoprotective Antibodies to <i>Escherichia coli</i> 0111 Rough Mutant J5, <i>The Journal of Infectious Diseases</i> , Vol. 151, No. 6 (1985) 995-1003
MS	KL	Sakulramung, R. et al., "Antigenic and Immunogenic Characteristics of Subcellular Fractions and Whole Cells of a Rough <i>E. Coli</i> 0111 (J5) Mutant", <i>Immunobiol.</i> Vol. 169 (1985) 372-388
MS	KM	Saladino, Richard et al., "Efficacy of a Recombinant Endotoxin Neutralizing Protein in Rabbits with <i>Escherichia coli</i> Sepsis", <i>Circulatory Shock</i> (1994) 42: 104-110
MS	KN	Schlecht, S. et al., "Nachweis von Antikörpern gegen Salmonella-R-Antigene in Salmonella-O-Antiseren", <i>Zbl. Bakt. I. Abt. Orig.</i> (1971) 216: 472-482
MS	KO	Schulkind, M.L. et al., "The Specific Secondary Biological Activities of Rabbit IgM and IgG Anti- <i>Salmonella typhimurium</i> 'O' Antibodies Isolated During the Development of the Immune Response", <i>Immunology</i> (1972) 23: 159-170
MS	KP	Schwartz, T.A. et al., "Immunochemical Specificity of Human Antibodies to Lipopolysaccharide from the J5 Rough Mutant of <i>Escherichia coli</i> 111:B4", <i>The Journal of Infectious Disease</i> , Vol. 159, No. 1 (1989) 35-42
MS	KQ	Senior, Judith et al., "Dehydration-rehydration vesicle methodology facilitates a novel approach to antibody binding to liposomes", <i>Biochimica et Biophysica Acta</i> (1989) 1003: 58-62
MS	KR	Shenep, Jerry L. et al., "Role of Antibiotic Class in the Rate of Liberation of Endotoxin During Therapy for Experimental Gram-Negative Bacterial Sepsis", <i>The Journal of Infectious Diseases</i> , Vol. 151, No. 6 (1985) 1012-1018
MS	KS	Somerville, John E. et al., "A Novel <i>Escherichia coli</i> Lipid A Mutant that Produces an Antiinflammatory Lipopolysaccharide", <i>J. Clin. Invest.</i> , Vol. 97, No. 2 (1996) 359-365


Examiner Signature R. P. SWARTZ	Date Considered 2-20-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08213-007001	Application No. 09/423,546
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Elliott Bennett-Guerrero et al.	
		Filing Date November 12, 1999	Group Art Unit 1645
(37 CFR §1.98(b))			

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	LA	Stack, Anne E. et al., "Failure of prophylactic and therapeutic use of a murine anti-tumor necrosis factor monoclonal antibody in <i>Escherichia coli</i> sepsis in the rabbit", Critical Care Medicine, Vol. 23, No. 9 (1995) 1512-1518
	LB	Su, Shidong et al., "Analysis of the Immune Response to Lipopolysaccharide", The Journal of Immunology, Vol. 145, No. 9 (1990) 2994-3001
	LC	Suffredini, Anthony F. et al., "The Cardiovascular Response of Normal Humans to the Administration of Endotoxin", N.E. Journal of Medicine (1989) 280-287
	LD	Tamauchi et al., "Enhancement of immunogenicity by incorporation of lipid A into liposomal model membranes and its application to membrane-associated antigens" (1983) 50: 605-612
	LE	Tonoli, M. et al., "The anti-lipid A antibody HA-1A binds to rough Gram-negative bacteria fixes complement and facilitates binding to erythrocyte CRI (CD35), Clin. Exp. Immunol. (1993) 92: 232-238
	LF	Trautmann, M. et al., "Antiserum Against <i>Escherichia coli</i> J5: A Re-evaluation of its In vitro and In vivo Activity Against Heterologous Gram-negative Bacteria", Infectious 13 (1985) 140-145
	LG	Tsai, Chao-Ming et al., "Heterogeneity and Variation Among <i>Neisseria meningitidis</i> Lipopolysaccharides", Journal of Bacteriology, Vol. 155, No. 2 (1983) 498-504
	LH	United States Pharmacopeia, "Pyrogen Test", The National Formulary, USP 23, NF 18, (1995) 151
	LI	Van Deventer, Sander et al., "Endotoxaemia: An Early Predictor of Septicaemia in Febrile Patients", The Lancet (1988) 605-608
	LJ	Van Rooijen et al., "Endotoxin Enhanced Adjuvant Effect of Liposomes, Particularly When Antigen and Endotoxin are Incorporated within the Same Liposome", Immunological Communications (1980) 747-757
	LI	Warren, H. Shaw et al., "Sounding Board - Anti-Endotoxin Monoclonal Antibodies", Vol. 326, No. 17 (1992) 1153-1157
	LJ	Warren, H. Shaw et al., "Assessment of Ability of Murine and Human Anti-lipid A Monoclonal Antibodies to Bind and Neutralize Lipopolysaccharide", J. Exp. Med., Vol. 177 (1993) 89-97
	LK	Warren, H.S. et al., "Endotoxin Neutralization with Rabbit Antisera to <i>Escherichia coli</i> J5 and Other Gram-Negative Bacteria", Infection and Immunity, Vol. 55 (1987) 1668-1673
	LM	Wassef, Nabila M. et al., "Liposomes as Carriers for Vaccines", Immunomethods (1994) 4: 217-222
	LN	Weintraub, Andrej et al., "Chemical and Immunochemical Analyses of <i>Bacteroides fragilis</i> Lipopolysaccharides", Infection and Immunity (1995) 197-201
	LO	Wells et al., "Anti-pseudomonas activity of anti-lipopolysaccharide hyperimmune equine plasma", Clin. Exp. Immunol. (1987) 68: 86-92
	LP	Wells et al., "Radiation Induced Gram Negative Bacteremia and Endotoxemia in Rabbits: Modification by Anti-Lipopolysaccharide Hyperimmune Equine Plasma", Life Sciences, Vol. 40 (1987) 2543-2550
	LQ	Wells et al., "Anti-LPS Antibodies Reduce Endotoxemia in Whole Body <sup>60</sup> Co Irradiated Primates: A Preliminary Report", Aviation, Space and Environmental Medicine (1990) 802-806
	LR	Wells et al., "Properties of equine anti-lipopolysaccharide hyperimmune plasma: binding to lipopolysaccharide and bactericidal activity against gram-negative bacteria", J. Med Microbiol., Vol. 24 (1987) 187-196

Examiner Signature



Date Considered


2-20-02

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08213-007001	Application No. 09/423,546
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Elliott Bennett-Guerrero et al.	
		Filing Date November 12, 1999	Group Art Unit 1645

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
MS	LS	Wolff, Sheldon et al., "Quantitative aspects of the pyrogenic response of rabbits to endotoxin", Lab. Clin. Investigations (1965) 268-276
MS	MT	Wong et al., "Liposome potentiation of humoral immune response to lipopolysaccharide and O-polysaccharide antigens of <i>Brucella abortus</i> ", Immunology (1992) 77: 123-128
MS	MU	Wood, David et al., "Reactivity of Monoclonal Antibody E5® with Endotoxin", Circulatory Shock (1992) 38: 55-62
MS	MV	Zellner, P.R. et al., "Active Immunization against <i>Pseudomonas aeruginosa</i> in Burns", 499-508



Examiner Signature <i>[Signature]</i>	Date Considered 2-20-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	